Recent MS Articles
Multiple sclerosis (MS) is a chronic disease of the central nervous system that affects more than 2.3 million people worldwide. MS is usually diagnosed in patients between 20 and 40 years of age, more commonly in women than in men.
RNI is currently enrolling patients who experience Central Neuropathic Pain (CNP) as a result of their MS. For more information contact Leigh Kreshel at 913-894-1500 ext. 155.
Researchers are conducting a study to evaluate an investigational drug for spasticity in people with MS. View more information about this clinical trial. As one of the MS centers participating in the study, Rowe Neurology Institute is now enrolling patients.
Robert Reed walked into a dermatologist’s office to have a couple moles checked. The bills he received included charges for an “operating room.”
If you want to understand a book, don’t open it in the middle. We at RNI place unusual emphasis on patient histories, even more unusual in this age of numbers-driven healthcare (and numbers-driven everything else, too).
October is designated as Physical Therapy Month and to celebrate the physical therapists from the Multiple Sclerosis Center at Rowe Neurology Institute (RNI) wanted to give something back to an incredible group of patients. On October, 11th 2012, RNI hosted the 3rd Annual Multiple Sclerosis,
MidAmerica Neuroscience Institute’s Doug Schell APRN, MSCN will be providing education and information about MS to patients, family members, and health care professionals at numerous upcoming events. Schell will speak on MS and the medication Gilenya on Thursday, August 30th at 6:00 PM
3RD ANNUAL MS PT NIGHT & Wii BOWLING TOURNEY Event Style: Open House Date: October 11th, 2012 Time: 5pm to 8:30pm Please bring your caregiver, spouse or friend! Join us for our 3rd annual multiple sclerosis physical therapy night!! We
After nearly three decades of service to the Kansas City area, and in honor of its founder, the MidAmerica Neuroscience Institute is announcing a name change to Rowe Neurology Institute.
Dr. Rowe reacts to a recent study, which is reporting that the MS drugs widely used to reduce relapses or MS flare-ups, specifically interferon beta, do not slow progression toward disability.